Immediate administration of mineralocorticoid receptor antagonist spironolactone prevents post-infarct left ventricular remodeling associated with suppression of a marker of myocardial collagen synthesis in patients with first anterior acute myocard
about
Postinfarct Left Ventricular Remodelling: A Prevailing Cause of Heart FailureEarly eplerenone treatment in patients with acute ST-elevation myocardial infarction without heart failure: the Randomized Double-Blind Reminder StudySex-specific impact of aldosterone receptor antagonism on ventricular remodeling and gene expression after myocardial infarction.Impact of aldosterone antagonists on the substrate for atrial fibrillation: aldosterone promotes oxidative stress and atrial structural/electrical remodelingA history of systemic hypertension and incident heart failure hospitalization in patients with acute myocardial infarction and left ventricular systolic dysfunction.The N-terminal propeptide of type III procollagen in patients with acute coronary syndrome: a link between left ventricular end-diastolic pressure and cardiovascular events.Cardiac hypertrophy and fibrosis in the metabolic syndrome: a role for aldosterone and the mineralocorticoid receptorNADPH oxidases in cardiovascular disease: insights from in vivo models and clinical studies.Clinical and echocardiographic correlates of plasma procollagen type III amino-terminal peptide levels in the communityMineralocorticoid receptor blockade: new insights into the mechanism of action in patients with cardiovascular disease.The relationship between serum markers of collagen turnover and cardiovascular outcome in the elderly: the Cardiovascular Health StudyThe role of aldosterone in heart failure and the clinical benefits of aldosterone blockade.Mineralocorticoid receptor antagonist pretreatment to MINIMISE reperfusion injury after ST-elevation myocardial infarction (the MINIMISE STEMI Trial): rationale and study design.Recent advances in the secondary prevention of coronary heart disease.Pathophysiology of heart failure following myocardial infarctionAldosterone receptor antagonism in heart failure.Hemodynamic effects of renin-angiotensin-aldosterone inhibitor and β-blocker combination therapy vs. β-blocker monotherapy for portal hypertension in cirrhosis: A meta-analysisAldosterone--a hormone of cardiovascular adaptation and maladaptation.Why are mineralocorticoid receptor antagonists cardioprotective?Urinary albumin excretion and the renin-angiotensin system in cardiovascular risk management.Fibroblasts in myocardial infarction: a role in inflammation and repair.Mineralocorticoid receptor antagonism: therapeutic potential in acute heart failure syndromes.Heart failure after myocardial infarction: clinical implications and treatment.Biomarkers: optimizing treatment guidance in heart failure.Targeting the aldosterone pathway in cardiovascular disease.Should torsemide be the loop diuretic of choice in systolic heart failure?Targeting the renin-angiotensin-aldosterone system in heart failure.Aldosterone receptor antagonists: current perspectives and therapiesEffects of eplerenone on transcriptional factors and mRNA expression related to cardiac remodelling after myocardial infarction.Treatment of heart failure with ACE inhibitors and beta-blockers: what is next? Aldosterone receptor antagonists?Reducing Cardiac Fibrosis: Na/K-ATPase Signaling Complex as a Novel TargetEffect of spironolactone on cardiac remodeling after acute myocardial infarction.Mineralocorticoid receptors, corticosteroids and the heart: where do we stand?Plasma aldosterone levels are associated with increased cardiovascular mortality: the Ludwigshafen Risk and Cardiovascular Health (LURIC) study.Timing of eplerenone initiation and outcomes in patients with heart failure after acute myocardial infarction complicated by left ventricular systolic dysfunction: insights from the EPHESUS trial.Effects of eplerenone, a selective aldosterone blocker, on the progression of left ventricular dysfunction and remodeling in rats with dilated cardiomyopathy.Aldosterone antagonism in heart failure: improvement of cardiac remodelling, endothelial dysfunction and platelet activation.Long-term effect of efonidipine therapy on plasma aldosterone and left ventricular mass index in patients with essential hypertension.Procollagen type III amino-terminal propeptide: a serum biomarker of left ventricular remodelling in paediatric dilated cardiomyopathy.Effects of aldosterone blockade on left ventricular function and clinical status during acute myocardial infarction.
P2860
Q26753845-C807B3C2-8F84-4A68-A2D2-DEB2D49579C0Q28239094-AA9C3685-F503-4275-8F17-4E87568F75A7Q33585711-307E37BE-E1DA-4ED9-8817-991902B8B915Q33775560-DB032691-D43A-41BD-9903-C3BD078197A4Q34076076-844D201E-FB6B-414E-AD61-5B705011A663Q34822562-ED329C0D-204E-4422-9C3D-26ED186EDFF7Q35071304-3D54F140-C033-43BB-870B-E135F2F5A06BQ35145985-7A4D364E-A50A-47B8-93F9-EF52BB00948CQ35207721-5627DCFF-8930-407F-99F8-9701EB77FEB8Q35580143-687D35E0-0330-4307-9652-CFEFC8AC61F1Q35686798-A38B89C4-B682-48C9-8CC3-439CC6B87C38Q35706823-1DD6BAB9-B26F-47F5-8813-60643F2E27F7Q35810347-6E51BCC4-0A04-4DA8-81CA-7792C35CE5C3Q35925701-6523613C-A74D-40FB-B7C2-AE7D36217023Q36098654-B0C96041-A9C8-41D9-B588-751FD8530303Q36277944-E503B25E-5E52-4ACC-B4F4-29D42A972DFCQ36387949-E87FE91D-9504-441D-8D21-FE71D91C9369Q36392694-E8F8708B-1E88-4692-8B8C-25C0D21A5BAAQ36639935-92D30BA4-6158-46FB-AD20-2525D55DC7D7Q36675396-F1A6C94C-F9ED-473C-8722-A740C2ADE9DFQ37716851-309ED237-B92C-4F56-9982-80CD6B635E36Q37889518-B6CC5099-2F92-4B38-AA8F-41EDA1444F5DQ37891910-BEC4B7DE-31C3-45E3-A760-9353DF89B3CDQ37903747-51D39E6D-3DAC-4E10-BF32-457973807B2DQ37951665-CDC4F488-6C93-49E1-8EE1-F1992E6D121EQ38046623-0EDC666E-91BB-4AFE-8292-958604A7604BQ38074092-D6694F90-59AC-4297-A12F-6CDDCA48E474Q38120241-F2B756EE-70BE-4C03-AE56-53EF84A81394Q41977722-34F4F509-3E8D-40BA-BA7A-5BA911D0D036Q42046045-F7C86075-B84E-4C8F-80AB-D045FC223E4DQ42375617-910D3846-6F9D-4711-A7A7-F37E9A406CA6Q42785044-CCB94F85-73E2-42FE-9E9A-D0F6628F3F3AQ42827657-BAB1CBB8-EAB5-4CA9-A698-975ADBD7FEB9Q43143859-66257AA7-2389-4521-A6D7-676034A6752AQ43252263-C6325CC1-8964-47B2-B06E-51BAF5809E39Q45092434-8B0C3596-44F9-4578-9E09-59B5C20A4C57Q45097794-D380869C-D15A-4CD4-BC83-738D730C1C59Q45981857-04F2AB82-CB1A-4724-B2A8-2F0E77C91874Q46014437-25719A02-6C39-4CE2-881A-E70A9647EB01Q46060609-DBED0622-B4B4-4CC5-BA83-59BF3753EF85
P2860
Immediate administration of mineralocorticoid receptor antagonist spironolactone prevents post-infarct left ventricular remodeling associated with suppression of a marker of myocardial collagen synthesis in patients with first anterior acute myocard
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Immediate administration of mi ...... h first anterior acute myocard
@en
Immediate administration of mi ...... h first anterior acute myocard
@nl
type
label
Immediate administration of mi ...... h first anterior acute myocard
@en
Immediate administration of mi ...... h first anterior acute myocard
@nl
prefLabel
Immediate administration of mi ...... h first anterior acute myocard
@en
Immediate administration of mi ...... h first anterior acute myocard
@nl
P2093
P1433
P1476
Immediate administration of mi ...... h first anterior acute myocard
@en
P2093
Atsushi Taniguchi
Atsuyuki Wada
Chitose Ishii
Keijin Ohno
Ken Kataoka
Masahiko Kinoshita
Masanori Fujii
Masaru Hayashi
Masato Ohnishi
Minoru Horie
P304
P356
10.1161/01.CIR.0000068340.96506.0F
P407
P577
2003-05-05T00:00:00Z